Brett Wertman, MD
Cardiovascular Disease · Mission Viejo, CANPI 1043349772
Payments from drug & device makers
Across 195 payments — averaging $32.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotronik Inc.$3K
- Novartis$567
- Boehringer Ingelheim$280
- Amgen$235
- Atricure, Inc.$198
- Astellas Pharma US Inc$198
- plus $2K from 24 others
What the payments were for
- Food & beverage$6,02094%
- Education$4086%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotronik Inc. | 65 | $3,115 |
| Novartis | 27 | $567 |
| Boehringer Ingelheim | 19 | $280 |
| Amgen | 12 | $235 |
| Atricure, Inc. | 2 | $198 |
| Astellas Pharma US Inc | 2 | $198 |
| Medtronic(2 entities) | 7 | $177 |
| AstraZeneca | 8 | $173 |
| Pfizer | 6 | $167 |
| Bayer | 3 | $156 |
| Boston Scientific | 6 | $155 |
| AOP Health US, LLC | 1 | $140 |
| E.r. Squibb & Sons, L.L.C. | 6 | $133 |
| Sanofi-aventis U.S. LLC | 3 | $95 |
| Edwards Lifesciences | 4 | $93 |
| Novo Nordisk | 3 | $75 |
| Merck | 3 | $67 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $50 |
| Scpharmaceuticals Inc. | 1 | $44 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $44 |
| Abbott | 2 | $37 |
| Abiomed | 1 | $37 |
| Johnson & Johnson | 2 | $34 |
| Altathera Pharmaceuticals LLC | 1 | $28 |
| Impulse Dynamics (USA) Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $23 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Kestra Medical Technology Services, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BioMonitor$485
- Rapiblyk$280
- Orsiro Mission$245
- Solia$238
- Edora$238
- Acticor$238
- Rivacor$238
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$159
- Edora 8 DR-T$123
- Acticor 7 VR-T DX$123
- Rivacor 7 DR-T$123
- Kerendia$112
How this compares
$6,428 in reported general payments places this provider in the 65th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 259 | $313,573 |
| EntrestoSacubitril/Valsartan | 143 | $157,677 |
| Repatha SureclickEvolocumab | 112 | $131,657 |
| XareltoRivaroxaban | 54 | $70,848 |
| MounjaroTirzepatide | 52 | $65,646 |
| FarxigaDapagliflozin Propanediol | 45 | $49,707 |
| Repatha SyringeEvolocumab | 27 | $35,396 |
| BrilintaTicagrelor | 30 | $29,986 |
| JardianceEmpagliflozin | 26 | $24,662 |
| Praluent PenAlirocumab | 12 | $17,562 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 145 | $6,042 |
| Nebivolol Hcl | 108 | $6,024 |
| Valsartan | 183 | $5,911 |
| EdarbiAzilsartan Medoxomil | 12 | $5,791 |
| Ranolazine ErRanolazine | 32 | $4,146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $167 | $313,573259 claims |
| NovartisEntresto | $567 | $157,677143 claims |
| AstraZenecaFarxiga, Brilinta | $173 | $79,69275 claims |
| Johnson & JohnsonXarelto | $34 | $70,84854 claims |
| Lilly USA, LLCMounjaro | $23 | $65,64652 claims |
| Boehringer IngelheimJardiance | $280 | $24,66226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Mission Viejo
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Lori DanielsSan Diego$10.2M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
- Jason RogersSacramento$5.1M
- Yu-Ping WangStanford$3.8M
- Yogesh PaliwalPomona$3.3M
- Farhad RafiiWest Hills$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.